GeneDx is trading at $98.94, up 4.54%, with no major announcement or direct catalyst identified for September 16, 2026; the move suggests continued momentum.
- Recent coverage centers on the September 9 NPC GenomeComplete collaboration.
- Shares gained 5.46% on September 15 and 5.25% on September 14.
- Broader Nasdaq strength may be supportive, while biotech-sector weakness limits confidence in a sector-wide explanation.